Sells medicines for rare liver diseases and other rare disorders to pharmacies and distribution partners.
10-K for FY2025, filed Feb 25, 2026We have three approved medicines: LIVMARLI® (maralixibat) (“Livmarli”), CHOLBAM® (cholic acid) capsules (“Cholbam”), and CTEXLI®…View ↗
Livmarli is a novel, orally administered, minimally-absorbed ileal bile acid transporter (“IBAT”) inhibitor (“IBATi”) that is approved for…View ↗
The U.S. Food and Drug Administration (“FDA”) approved Cholbam in March 2015 as the first FDA-approved treatment for pediatric and adult…View ↗
Our approved medicines are currently distributed in the U.S. and Canada, through a single specialty pharmacy in each country. In other…View ↗
Pharmacies and distribution partners pay for approved medicines when the products are delivered. License and collaboration arrangements can also bring upfront fees, milestone payments and royalties tied to product sales.
10-K for FY2025, filed Feb 25, 2026The Company recognizes product sales, net when the customer obtains control of its product, which occurs at a point in time, typically upon…View ↗
The terms of the Company’s license and collaborative research and development agreements include upfront license fees, research…View ↗
For arrangements that include sales-based royalties, including milestone payments based on the level of sales, the Company recognizes…View ↗
$521.3M
10-K for FY2025, filed Feb 25, 2026
$521.3M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Total product sales, net
Sold outright
10-K for FY2025, filed Feb 25, 2026 |
100%
FY2022: 97%
|
Total product sales, net, FY2025
$521.3M Sources
|
Sold outright |
|
License and other revenue
Licensed
|
0.0%
FY2022: 2.6%
|
License and other revenue, FY2025
$0 Sources
|
Licensed |
In the U.S. and Canada, specialty pharmacies distribute its medicines; elsewhere, pharmacies receive them through logistics providers, authorized distributors or licensed partners. Governments place periodic orders in some countries.
10-K for FY2025, filed Feb 25, 2026Our approved medicines are currently distributed in the U.S. and Canada, through a single specialty pharmacy in each country. In other…View ↗
Not on paper. It lost $23.4M in FY2025, but brought in more cash than it spent: $54.9M of free cash flow.
10-Q for Q3 FY2026, filed Nov 3, 2026
−$40.8MView ↗
10-Q for Q3 FY2026, filed Nov 3, 2026
Open tableView ↗
8-K, filed Sep 28, 2026
On September 25, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) and Incyte Corporation (“Incyte”) announced that the U.S. Food and Drug…View ↗
Growing. Revenue grew 27.2x in 4 years, from $19.1M in FY2021 to $521.3M in FY2025, about 128% a year.
Broader commercial portfolio
The older report described Livmarli as its commercial product and volixibat as a candidate; the latest report also describes Cholbam and Ctexli as marketed medicines.
10-K for FY2022, filed Mar 8, 2023 10-K for FY2025, filed Feb 25, 2026
Livmarli’s PFIC status
The older report described Livmarli as approved for ALGS and under development for PFIC; the latest report describes it as approved for PFIC in several markets.
10-K for FY2022, filed Mar 8, 2023 10-K for FY2025, filed Feb 25, 2026Our product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter (“IBAT”) inhibitor (“IBATi”), is…View ↗
Livmarli is a novel, orally administered, minimally-absorbed ileal bile acid transporter (“IBAT”) inhibitor (“IBATi”) that is approved for…View ↗
Competes with GSK, Ipsen Pharma, Alfasigma, Gilead Sciences, Vir Biotechnology, Shionogi &, Harmony Biosciences, Dr. Falk Pharma, Leadiant Biosciences, Laboratoires CTRS, Zydus Therapeutics, Calliditas Therapeutics, NGM Biopharmaceuticals, Chemomab Therapeutics, and Pliant Therapeutics
10-K for FY2025, filed Feb 25, 2026We are aware of two other companies pursuing clinical development and commercialization of therapies that reduce sBA levels via the IBAT…View ↗
Loading...